Relapse in leprosy after 24 months of who multidrug therapy
DOI:
https://doi.org/10.47878/hi.2009.v34.35163Abstract
The WHO multidrug therapy has changed the leprosy scenario since its implementation, with a low relapse rate. However, it is still a challenge the duration of treatment for effective cure in patients with high bacillary load. We report in this article a relapse in a patient 9 years after he had finished the therapy. It is also discussed the diagnostic criteria for leprosy relapse and the possibility that some patients require a longer treatment than the usually preconized.
Downloads
Download data is not yet available.
References
1 Jain S, Sehgal VN. Multidrug therapeutic challenges in leprosy. Int J Dermatol. 1997;36:493-6
2 Water MF. Chemotherapy of Leprosy- current status and future prospects. Trans R Soc Trop Med Ryg 1993;87:500-503
3 Avelleira J.C.R. et.al. Persistência de bacilos viáveis em pacientes de hanseníase multibacilar altamente bacilíferos após doze doses do esquema poliquimioterápico (PQT/OMS) Hansen Int 2003;28(1):44-8
4 Ministério da Saúde. Guia para o controle da hanseníase. Brasília: Departamento de Atenção Básica, Secretaria de Políticas de Saúde, Ministério da Saúde. 2002
5 Editorial. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev 2001;72:3-7
6 Poojabylaiah M, Marne R, Varikkodan R, Bala N, Dandakeri S. Relapses in multibacillary leprosy patients after multidrug therapy. Lepr Rev 2008;79:320–4
7 Trindade MAB, Fleury RN, Alchorne MMA. Evolução histológica de reativações da hanseníase durante ou após o tratamento. Tese. São Paulo, 1996
8 Kaimal S, Thappa DM. Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009; 75(2):126-35
9 Gallo MEN, Oliveira MLW. Relapses and reinfection in leprosy. Medicina, Ribeirão Preto 1997;30:351-7
10 Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev 2005;76:241-52
11 Hall RP. Dapsone. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia (PA): W.B Saunders
Company; 2001. p230-50.
2 Water MF. Chemotherapy of Leprosy- current status and future prospects. Trans R Soc Trop Med Ryg 1993;87:500-503
3 Avelleira J.C.R. et.al. Persistência de bacilos viáveis em pacientes de hanseníase multibacilar altamente bacilíferos após doze doses do esquema poliquimioterápico (PQT/OMS) Hansen Int 2003;28(1):44-8
4 Ministério da Saúde. Guia para o controle da hanseníase. Brasília: Departamento de Atenção Básica, Secretaria de Políticas de Saúde, Ministério da Saúde. 2002
5 Editorial. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev 2001;72:3-7
6 Poojabylaiah M, Marne R, Varikkodan R, Bala N, Dandakeri S. Relapses in multibacillary leprosy patients after multidrug therapy. Lepr Rev 2008;79:320–4
7 Trindade MAB, Fleury RN, Alchorne MMA. Evolução histológica de reativações da hanseníase durante ou após o tratamento. Tese. São Paulo, 1996
8 Kaimal S, Thappa DM. Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009; 75(2):126-35
9 Gallo MEN, Oliveira MLW. Relapses and reinfection in leprosy. Medicina, Ribeirão Preto 1997;30:351-7
10 Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev 2005;76:241-52
11 Hall RP. Dapsone. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. Philadelphia (PA): W.B Saunders
Company; 2001. p230-50.
Downloads
Published
2009-06-30
How to Cite
1.
Fogagnolo L, Martelli ACC, Fleury RN, Nascimento DC do, Diório SM. Relapse in leprosy after 24 months of who multidrug therapy. Hansen. Int. [Internet]. 2009 Jun. 30 [cited 2024 May 20];34(1):49-53. Available from: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35163
Issue
Section
Relatos de Experiências
License
This journal is licensed under a Creative Commons Attribution 4.0 International License.
